Clinical trials: Prostate Disease
Bone Cancer, Bone Metastases
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
The goal of this study is to collect comparative data on safety and efficacy of MR Guided Focused Ultrasound and External Beam Radiation for treatment of metastatic bone tumors or multiple myeloma.
- Conditions
- Bone Cancer, Bone Metastases, Pain
- Trial name
- NCT01091883
- Testing
- Exablate treatment, Radiation
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- InSightec
Benign Prostatic Hyperplasia
Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III
A dual-arm prospective, interventional clinical trial to evaluate the safety and performance of obtaining hemostasis with catheters along with the use or absence of a hemostatic agent following treatment with the AQUABEAM System.
- Trial name
- AHAIII (NCT04308070)
- Testing
- AQUABEAM System followed by catheter without hemostatic agent, AQUABEAM System followed by catheter with hemostatic agent
- Where
- India
- Volunteers
- 26 people
- Sponsor
- PROCEPT BioRobotics
Metastatic Prostate Cancer
One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™
This is an open-label, single-arm, multi-center extension study to evaluate safety in patients with mCRPC of YONSA 500 mg (4 x 125 mg qd) with methylprednisolone (4 mg bid).
- Trial name
- NCT02962284
- Testing
- abiraterone acetate with Methylprednisolone
- Volunteers
- 20 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Clinical Evaluation of the Efficacy and Safety of a Medical Device in the Form of Rectal Suppositories (Prospidol®) for the Treatment of Symptoms Associated With Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
The goal of this clinical trial is to evaluate whether a medical device is effective and safe in treating chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in adult men.
- Trial name
- NCT07685847
- Testing
- Prospidol suppository
- Where
- 2 sites in Italy
- Volunteers
- 40 people
- Sponsor
- S&R Farmaceutici S.p.A.
Prostate Cancer
Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer
The purpose of this study is to determine whether the new RNActive®-derived prostate cancer vaccine CV9104 prolongs survival in patients with asymptomatic or minimally symptomatic metastatic prostate cancer that is castrate…
- Trial name
- NCT01817738
- Testing
- CV9104
- Where
- 48 sites in Czechia, France and 6 more
- Volunteers
- 197 people
- Sponsor
- CureVac
Prostatic Hyperplasia
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
Patients who are currently symptomatic and have been diagnosed with BPH by a physician may qualify for this 20-week study. Patients must not be diabetic, must not have prostate cancer and must not have had any surgery to repair…
- Trial name
- NCT00044226
- Testing
- ML-04A
- Where
- 14 sites in United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Milkhaus Laboratory
Prostate Cancer
A Study of Degarelix in Patients With Prostate Cancer
The purpose of this study was to see if giving Degarelix every month for 7 months then stop treatment for 7 months (intermittent therapy) would show a reduction of negative effects of androgen deprivation therapy by increasing…
- Trial name
- NCT00928434
- Testing
- Degarelix, Leuprolide
- Where
- 59 sites in United States
- Volunteers
- 409 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
An Open-label Extension Study of PSMA ADC 2301 in mCRPC
PSMA ADC 2301EXT is an open-label study to further assess the anti-tumor activity as measured by radiographic imaging and biomarkers, safety and tolerability of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA…
- Trial name
- NCT02020135
- Testing
- PSMA ADC
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer
Stratagen Quantitative Prostate MRI Platform Pilot Study
The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions.
- Trial name
- NCT06985238
- Testing
- MRI
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Stratagen Bio, Inc.
Melanoma, Breast Cancer
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)
Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4 melanoma, prostate and breast cancer. This is a dose escalation, safety study.
- Conditions
- Melanoma, Breast Cancer, Prostate Cancer
- Trial name
- PSX-X04 (NCT00636558)
- Testing
- CVA21
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Viralytics
Prostate Cancer, Prostate Adenocarcinoma
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
- Trial name
- Solar-Recur (NCT06235099)
- Testing
- Copper Cu 64 PSMA I&T
- Where
- 31 sites in United States
- Volunteers
- 235 people
- Sponsor
- Curium US LLC
Prostate Cancer
An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer
This trial is an open-label, multi-centre, single arm extension for the 000006 trial in Chinese patients with prostate cancer. Eligible patients will receive monthly (28-day intervals) maintenance doses of 80 mg (20 mg/mL)…
- Trial name
- PandaExtension (NCT02015871)
- Testing
- Degarelix
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Ferring Pharmaceuticals
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Prostatic Hyperplasia
SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fast Admin
It will be an open-label, randomized, laboratory-blind, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the healthy male volunteers under fasting conditions receive, in each period, the test formulation…
- Trial name
- NCT01262989
- Testing
- Test formulation, Reference formulation
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metastatic Androgen Independent Prostate Cancer
Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)
- Trial name
- NCT00849290
- Testing
- APC8015F
- Where
- 58 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Dendreon
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy…
- Conditions
- Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
- Trial name
- NCT04104776
- Testing
- Tulmimetostat, Enzalutamide
- Where
- 80 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Hormone-Refractory Prostate Cancer
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
The objective of MER-101-03 is to examine the effects of two different dosing regimens of MER-101 20mg tablets versus Zometa 4mg IV infusion once-monthly therapy.
- Trial name
- NCT00636740
- Testing
- Zoledronic Acid 20mg Tablets, Zoledronic Acid
- Where
- 13 sites in United States, Estonia and 1 more
- Volunteers
- 30 people
- Sponsor
- Merrion Pharmaceuticals, LLC
Prostate Cancer
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
It is the aim of this prospective, single-group, clinical study to assess whether bone parameters can be used as diagnostic tools for early detection of bone metastases in patients with high risk prostate cancer.
- Trial name
- NCT00391690
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 99 people
- Sponsor
- Novartis
Prostate Cancer
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
The purpose of this trial with Zometa is to investigate the effect ZOMETA 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing associated bone loss in prostate cancer patients with bone metastasis when…
- Trial name
- NCT00035997
- Testing
- Zometa
- Where
- 56 sites in United States
- Volunteers
- 261 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with…
- Trial name
- OSPREY (NCT02981368)
- Testing
- 18F-DCFPyL Injection, PET/CT imaging
- Where
- 10 sites in United States, Canada
- Volunteers
- 385 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.